Hopping Mad Over Drug Company Product Hopping [Forbes]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Forbes
Corrected, Jan. 15, 2026: This story originally stated that the state of California had sued Gilead. It has been updated to note that many individual plaintiffs sued the company. A group of plaintiffs is suing Gilead Sciences in the Superior Court of California for the County of San Francisco over its delay of an HIV drug, a move that critics of the pharmaceutical industry call “product hopping.” Regardless of how the lawsuit comes out, the company's actions strike me as deeply immoral and ought to leave all of us hopping mad. Here's what we know. In the late 1990s, Gilead was investigating two HIV drugs each with the same active ingredient: tenofovir. One of those drugs, eventually known as Stribild, received FDA approval in 2012. It was effective against HIV in early trials but had lots of side effects. A second drug looked more promising; it combined the active ingredient with other chemicals that significantly reduced the risk of side effects. The company recognized that th
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/15/26 - Form 144
- 1/15/26 - Form 144
- 1/5/26 - Form 4
- GILD's page on the SEC website